Ultrasonic aspiration in coronary artery surgery.

T. Mitsui,M. Onizuka,H. Ijima,H. Maeta,K. Okamura,A. Sakai,T. Tsutsui,K. Mitsui,M. Hori

DOI: https://doi.org/10.1016/S0003-4975(10)60021-5

1985-08-01

Abstract:

What problem does this paper attempt to address?

Prevalence of Red Blood Cell Alloimmunization Among Pediatric Patients With Sickle Cell Disease in Saudi Arabia

Badriah Al-Asmari,Abdullah Baothman,Mohammed Almohammadi,Mohammed Aljuaid,Wasil Jastaniah

DOI: https://doi.org/10.1097/mph.0000000000002889

2024-06-25

Journal of Pediatric Hematology/Oncology

Abstract:Objective: Sickle cell disease (SCD) is a common hereditary hemoglobin disorder worldwide. One of the main treatments for patients with SCD is the requirement for blood transfusions. Posttransfusion alloimmunization with red blood cell (RBC) antigens continues to be a major risk factor for SCD. The objective of this study was to determine the rate, nature, and risk factors of red cell alloimmunization among pediatric patients with SCD in our center and compare our results with published reports from Saudia Arabia SA, regional countries, and some international countries. Materials and Methods: A retrospective chart review of patients with SCD at King Abdulaziz Medical City–Jeddah, between 2008 and 2019 was performed. Demographic characteristics and transfusion histories were recorded. Blood samples were analyzed for alloimmunization using immunohematologic techniques. Results: In total, 121 patients were analyzed. Alloantibodies were detected in 21 patients (17.4%) and were mostly single in 15 patients (71.4%), anti-K (23.7%), anti-E (19.0%), and anti-S (9.5%). The other 6 patients (28.6%) had multiple alloantibodies, especially the combination of anti-C and anti-K (9.5%) and the combination of anti-C and anti-E (9.5%). Alloantibody levels were significantly higher in patients with frequent hospital admissions (>5 times annually), those who had an exchange blood transfusion, those younger than 3 years old, and those who received a larger number of blood units (P ≤0.05). Conclusion: The rate of RBC alloimmunization is determined and considered relatively low compared with that in other nations. Matching for extended RBC antigens to include ABO, RH (D, C, c, E, e), K, Fya, Fyb, Jka, and Jkb antigens in the screening panel for donors and recipients is highly recommended to ensure better transfusion practices and avoid transfusion-related complications.

oncology,pediatrics,hematology
Red blood cell alloimmunization in blood transfusion-dependent β thalassemia major patients in Sana'a City-Yemen

Mohammed A. W. Almorish,Boshra Al-absi,Ahmed M. E. Elkhalifa,Abdulaziz H. Alhamidi,Mohammad Abdelrahman

DOI: https://doi.org/10.1038/s41598-024-51561-2

IF: 4.6

2024-01-11

Scientific Reports

Abstract:The development of erythrocyte alloantibodies complicates transfusion therapy in β thalassemia major patients. These antibodies increase the need for blood and intensify transfusion complications. Data on erythrocyte alloimmunization is scarce in Yemeni thalassemia patients. We studied the frequency of alloimmunization in multitransfused β-thalassemia major patients and investigated risk factors that affect antibody formation. Blood samples were taken from 100 β thalassemia major patients who received multitransfused leukodepleted packed red-blood cells. Antibody screening and identification were performed by indirect antiglobulin test using the gel column technique. All patients were tested for autoantibodies using autocontrol and direct antiglobulin test. No adsorption test was done as no autoantibodies were detected in any patient. In our study of 100 β-thalassemia patients, 50 were male and 50 were female with ages ranging from 1 to 30 years. Alloantibodies were present in 6% of patients, while no autoantibodies were detected. Of the 17 alloantibodies identified, the majority were directed against Kell (41.2%) and Rh (29.4%) blood groups. Alloimmunization was significantly associated with age group and sex (p = 0.013, p = 0.030), respectively in β thalassemia major patients. The development of alloantibodies was not significantly associated with duration, total number of transfusions and splenectomy (P = 0.445, P = 0.125, P = 0.647). No autoantibodies found in patients with β thalassemia major. The study found low rates of erythrocyte alloimmunization in multitransfused β-thalassemia major patients, but significant alloantibodies were produced primarily from Kell and Rh blood groups, suggesting the need for providing phenotypically matched cells for selective antigens to improve transfusion efficiency.

multidisciplinary sciences
In vivo X-ray fluorescence estimation of bone lead concentrations in Queensland adults.

J. Price,H. Baddeley,J. Kenardy,B. J. Thomas,B. W. Thomas

DOI: https://doi.org/10.1259/0007-1285-57-673-29

British Journal of Radiology

Abstract:A group of 200 Queensland adults without known health problems had in-vivo estimation of finger bone lead concentrations using X-ray fluorescence analysis (XRF). Forty of these subjects had elevated levels of bone lead of 25 ppm or more, consistent with exposure to the metal. Although the correlation between Queensland residence during childhood and raised bone lead levels was not significant, there were significant correlations between childhood residence in a painted wooden house and raised levels, and between occupational exposure and raised levels. Of the 40 subjects with elevated lead levels only two had neither a history of occupational exposure or childhood residence in a wooden house, whereas 11 of the 25 who had a history of both occupational and residential exposure were positive. The data are consistent with lead in housepaint, or absorbed during occupational exposure, being the two major sources of raised bone lead concentrations.
Red blood cell extended antigen typing in Omani patients with sickle cell disease to enhance daily transfusion practice

Amal Salim Al Breiki,Salam Al Kindi,Lilian Castilho

DOI: https://doi.org/10.2478/immunohematology-2024-0014

2024-10-04

Immunohematology

Abstract:Many Omani patients with sickle cell disease (SCD) undergo red blood cell (RBC) transfusions that are only matched for ABO and D, making RBC alloimmunization a significant concern in this population. Currently, the integration of molecular assays and hemagglutination testing helps to determine RBC phenotypes and genotypes, facilitating the provision of compatible blood and minimizing additional alloimmunization risks in patients with SCD. Based on this finding, our objective was to use molecular methods to predict the extended antigen profile of Omani patients with SCD across various blood group systems including Rh, Kell, Duffy, Kidd, Colton, Lutheran, Dombrock, Diego, Cartwright, and Scianna. This approach aims to implement RBC matching strategies and enhance daily transfusion practices for these patients. Molecular methods encompassed multiplex polymerase chain reaction for RHD, BeadChip arrays for variants of RHD and RHCE, and ID CORE XT for the primary allelic variants of RBCs. This study enrolled 38 patients with SCD, comprising 34 patients with homozygous HbSS, 1 patient with HbSC, and 3 patients with HbS Oman. The predominant ABO blood group was group O, observed in 44.7 percent of patients, followed by group A in 21.1 percent and group B in 13.2 percent. The most prevalent Rh phenotype predicted from the genotype was D+C+E-c+e+, identified in 34.2 percent of patients. All patient samples were K-, exhibiting the k+ Kp(b+) Js(b+) phenotype, with 81.6 percent demonstrating Fy(a-b-) due to the homozygous FY*02N.01 genotype and 28.9 percent displaying Jk(a+b-). RH variant alleles were detected in five patients (13.2 %), with only one type of RHD variant (RHD*DIIIa) and one type of RHCE variant (RHCE*ceVS.02.01) identified. Alloantibodies were present in 26 patients (68.4%). This study presents the initial comprehensive report of extended RBC antigen profiling in Omani patients with SCD, revealing disparities in the prevalence of RBC phenotypes compared with SCD patients from other regions and countries. Furthermore, our findings underscore a high rate of alloimmunization in these patients, emphasizing the need to implement antigen-matching programs to improve daily transfusion practices.
Statistical Computing Environments and the Practice of Statistics in the Biopharmaceutical Industry

A. Hopkins,Susan P. Duke,S. Dubman

DOI: https://doi.org/10.1177/009286151004400104

2010-01-01

Abstract:A structured statistical computing environment (SCE) enhances rigor in operational implementation of statistical analyses of clinical studies through process transparency, allowing reproducibility of results by independent reviewers. Desirable features and associated benefits of an SCE system are described. Minimum SCE requirements discussed in detail consist of a structured programming environment, an operational analysis data repository, and a metadata-driven architecture containing information about data and status of various processes. The metadata provide a foundation for connecting multiple processes and systems, thereby allowing the creation of tools that largely automate the analysis process. Standards drive productivity enhancement for creating statistical deliverables based on metadata obtained from the development plan, protocols, and analysis plans. Not all the features discussed are available today in commercial systems. In the future, nearly all information about clinical trial analytics can be driven by a standards-based, metadata-driven architecture. To accomplish this goal, metadata need to be available about all the processes used to collect, transform, and analyze the patient data. Further standards development will be necessary to fully describe the entire statistical analysis process. Learning Objectives Upon completion of this article, participants should be able to do the following: Describe the elements of good statistical practice that contribute to establishing the credibility of clinical trial results. Describe the fundamental concept of statistical computing environment (SCE); the SCE as a programming environment; and as a clinical data platform and repository driven by a metadata architecture. Target Audience This article is informative for medical doctors working in the pharmaceutical industry; biostatisticians, statistical programmers, clinical data managers, and IT professionals.
Red blood cell alloimmunization in transfused patients with myelodysplastic syndromes: a retrospective study from northern China

Li Wang,Xiaoxin Xu,Shichun Wang,Ruidong Li,Pengyu Zhang

DOI: https://doi.org/10.1093/labmed/lmae056

2024-07-26

Abstract:Objective: Alloimmunization against red blood cell (RBC) antigen is an important concern in myelodysplastic syndromes (MDSs) patients with chronic transfusion, causing potential risk for hemolytic reaction and limited supply of compatible blood. However, there is little data addressing RBC alloimmunization in this patient cohort among the Chinese population. This study aims to evaluate the incidence, specificity of antibodies, and RBC units transfused before antibody formation and its significance in a population of patients consistently receiving RhD-matched RBC units. Methods: We retrospectively reviewed the transfusion and clinical information of all transfused patients with MDS enrolled in our hospital from 2012 to 2022. The cumulative incidence of alloimmunization was analyzed by a Kaplan-Meier plot. Alloimmunization incidence was compared based on different transfused RBC units using the log-rank test. Results: A total of 103 patients with MDS were included in this study; alloantibody formed in 8 (7.8%) patients. Before reaching 32 RBC units, 87.5% of the alloimmunized patients had developed their alloantibodies. All but 1 of the alloantibodies developed were antibodies to Rh antigens. The RBC transfusion intensity and frequency were significantly higher following alloimmunization in the alloimmunized patients (P = .008, P = .008, respectively). Conclusion: The antibodies detected mostly involve the Rh system among MDS patients in China. The alloimmunization tended to occur early prior to reaching 32 RBC units in patients with MDS. Rh antigen matching should be considered early in the patient's transfusion history and completed before receiving 32 RBC units.
Red cell alloantibodies in beta-thalassaemia major patients' blood referring to the regional blood transfusion center of Tehran, Iran

Parisa Ebrahimisadr,Zahra Bakhshandeh,Hamidreza Majidiani

DOI: https://doi.org/10.34172/bi.2021.20

Bioimpacts

Abstract:Introduction: Thalassemia is associated with a genetic decline in the rate of synthesis of one or more types of natural hemoglobin polypeptide chains. One of the major complications in thalassemia patients is alloimmunization, which is antibody production by the patient against transfused red blood cells (RBCs). These RBCs are unknown by the recipient and the formed antibodies against them are called alloantibodies. This study aimed to evaluate the frequency of alloantibodies against RBCs in beta-thalassemia patients referred to Tehran Regional Blood Transfusion Center. Methods: In this study, antibody screening tests (Dia-cell I, II, and III) were performed on 184 thalassemia patients. An identification test by the Dia panel consisting of 11 different O RBCs groups to examine sera with Dia cells (I, II, or III) was performed. Results: In our study, males and females patients comprised 66 (35.87%) and 118 (64.13%), respectively, of whom 116 (63%) had alloimmunization. In addition, 68 thalassemia subjects (37%) lacked alloantibodies. Among 184 patients with beta-thalassemia major, anti-K (Kell system), anti-D, and anti-E (Rhesus system) had the most abundant alloantibody variants with an incidence of 24 (13%), 11 (5.98%), and 10 (5.4%), respectively. Conclusion: Before RBC transfusion, regular RBC antigen phenotypes, as well as problem-solving of alloantibody production by receiving compatible blood for Kell and RH subgroups, are suggested for all cases of transfusion-derived thalassemia.
RH genotypes and red cell alloimmunization rates in chronically transfused patients with sickle cell disease: A multisite study in the USA

Narek Israelyan,Sunitha Vege,David F. Friedman,Zhe Zhang,Stacey Uter,Ross M. Fasano,Marianne Yee,Connie Piccone,Shannon Kelly,Jane S. Hankins,Yan Zheng,Connie M. Westhoff,Stella T. Chou

DOI: https://doi.org/10.1111/trf.17740

2024-02-01

Transfusion

Abstract:Background Red cell alloimmunization remains a challenge for individuals with sickle cell disease (SCD) and contributes to increased risk of hemolytic transfusion reactions and associated comorbidities. Despite prophylactic serological matching for ABO, Rh, and K, red cell alloimmunization persists, in part, due to a high frequency of variant RH alleles in patients with SCD and Black blood donors. Study Design and Methods We compared RH genotypes and rates of alloimmunization in 342 pediatric and young adult patients with SCD on chronic transfusion therapy exposed to >90,000 red cell units at five sites across the USA. Genotyping was performed with RHD and RHCE BeadChip arrays and targeted assays. Results Prevalence of overall and Rh‐specific alloimmunization varied among institutions, ranging from 5% to 41% (p = .0035) and 5%–33% (p = .0002), respectively. RH genotyping demonstrated that 33% RHD and 57% RHCE alleles were variant in this cohort. Patients with RHCE alleles encoding partial e antigens had higher rates of anti‐e identified than those encoding at least one conventional e antigen (p = .0007). There was no difference in anti‐D, anti‐C, or anti‐E formation among patients with predicted partial or altered antigen expression compared to those with conventional antigens, suggesting that variant Rh on donor cells may also stimulate alloimmunization to these antigens. Discussion These results highlight variability in alloimmunization rates and suggest that a molecular approach to Rh antigen matching may be necessary for optimal prevention of alloimmunization given the high prevalence of variant RH alleles among both patients and Black donors.

hematology
Red Cell Alloimmunization in Repeatedly Transfused Sudanese Patients with leukemia in Northern Sudan

Taj Alasfia Abdalkream Jawish,Hajir Mohamed Hessen,Mubarak Ahmed Alshafeea,Khalid Abdelsamea Mohamedahmed,Elhadi Abdella Ahmed,Gad Allah Modawe,Ibrahim Khider Ibrahim

DOI: https://doi.org/10.31557/APJCP.2023.24.1.21

2023-01-01

Abstract:Background: Leukemia frequently causes anemia; thus patients need products containing normal blood or RBCs for treatment. Anti-red blood cell alloantibody formation is still a critical challenge in transfusion. Objectives: The current study aimed to investigate RBC alloantibodies in Sudanese leukemia patients who receive multiple blood transfusions at the cancer center in Dongola and Maroyee, Northern Sudan. Materials and methods: At the Northern State oncology center in Dongola and Maroyee, Sudan, an across-sectional descriptive study design was used. In this study, 100 leukemic patients who had received blood transfusions three times or more were enrolled. From each participant, Peripheral blood was drawn in amounts of 3 ml in EDTA vacutainer tubes for ABO blood group and Rh factor testing and 3 ml in non-additive containers for antibody screening and Alloantibody identification. All individuals' ABO blood groups and Rh factors were determined using the slide method. Indirect Coombs test apply to detect alloantibodies by Polly Specific antihuman globulin reagents using tube method techniques. Alloantibody identification was performed by DiaMed-ID microtyping system. Results: Incidence of alloimmunization was 11%, with 11 alloantibodies found in 11 patients. The most common alloantibody was kell (36.4%), followed by Lea (27.2%; 3/11), then P (18.2%; 2/11) and M (18.2%; 2/11). Conclusion: Anti kell antibody was the most prevalent alloantibody among leukemic patients with multiple transfusions.
Red blood cell alloimmunizations in thalassaemia patients with regular transfusion in China: A systematic review and meta-analysis

Xinwei Zhang,Yuanli Li,Bin Yan,Xiaopeng Li,Aihua Sun,Shanying Gui

DOI: https://doi.org/10.1016/j.tracli.2023.02.001

Abstract:Objective: The development of red blood cell alloimmunization intensifies transfusion complication in thalassaemia patients. The purpose of this paper is to evaluate the existing evidence on the prevalence of erythrocyte alloimmunization in China by meta-analysis. We systematically searched cross-sectional studies regarding the alloimmunization of thalassaemia patients with regular blood transfusion in China from year 2000 to May 2021 in the Cochrane library, PubMed, EMBASE, Web of Science, and Chinese databases including CNKI, Wanfang Data, Vip and CBM. Data extraction and quality evaluation of the included studies were performed. Meta-analysis was performed using the DerSimonian and Laird random-effects models with inverse variance weighting. The presence of publication bias was tested by Egger's test, and the methodological quality of each included article was evaluated by the criteria specific to prevalence studies. Results: A total of 1874 patients and 263 alloantibodies from 11 studies were identified and included in the meta-analysis. The proportion of alloantibodies against antigens belonging to the Rh, MNSs and Kidd systems were as high as 70.3%, 17.9%, and 6.5%, respectively. Meta-analysis showed that the overall prevalence of alloimmunization among transfusion-dependent thalassaemia patients in China is 11.4% (95%CI: 7.2%∼16.3%). Conclusions: The characteristics of red blood cell alloimmunization among thalassaemia patients with regular transfusion in China differ greatly from those in other countries. Therefore, transfusion strategies shall be actively adapted in line with thalassaemia patients in China to minimize the risk of alloimmunization.
Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia

Marianne E.M. Yee,Cassandra D. Josephson,Anne M. Winkler,Jennifer Webb,Naomi L.C. Luban,Traci Leong,Sean R. Stowell,Ross M. Fasano

DOI: https://doi.org/10.1111/trf.14282

2017-08-24

Transfusion

Abstract:BACKGROUND: Red blood cell (RBC) alloimmunization occurs at a high frequency in sickle cell anemia (SCA) despite serologic matching for Rh (C/c, E/e) and K antigens. RBC minor antigen genotyping allows for prediction of antigens and RH variants that may lead to alloimmunization.STUDY DESIGN AND METHODS: RBC antigen genotyping was performed on chronically transfused pediatric SCA patients, using PreciseType human erythrocyte antigen (HEA), RHCE, and RHD BeadChip arrays. All patients received C/c, E/e, and K serologically matched units (Category 1); patients with prior RBC antibodies were also matched for Fya , Jkb , and any antibodies (Category 2). The RBC genotypes of all leukoreduced (LR) units transfused over a 12-month period were determined by the prototype HEA-LR BeadChip assay.RESULTS: There were 2320 RBC units transfused to 90 patients in 1135 transfusion episodes. Thirty-five (38.9%) patients had homozygous or compound heterozygous RH variants. Seven new alloantibodies were detected, with alloantibody incidence of 0.706 in 100 units for Category 2 transfusions and 0.068 in 100 units for Category 1 (p = 0.02). Three patients on Category 2 transfusions formed new anti-Jsa and had a higher rate of exposure to Jsa than those who did not form anti-Jsa (20.4 vs. 8.33 exposures/100 units, p = 0.02). The most frequent mismatches were S (43.9%), Doa (43.9%), Fya (29.2%), M (28.4%), and Jkb (28.1%).CONCLUSIONS: Alloimmunization incidence was higher in those with prior RBC antibodies, suggesting that past immunologic responders are at higher risk for future alloimmunization and therefore may benefit from more extensive antigen matching beyond C/c, E/e, K, Fya , and Jkb .

hematology
The effects of postmortem CT scanning all cases entering a UK public mortuary: a 3-month pilot

S. Suvarna,P. Kitsanta,J. Burton

DOI: https://doi.org/10.1136/jclinpath-2017-204505

2017-07-25

Journal of Clinical Pathology

Abstract:Autopsy work is currently principally used in the UK to derive a cause of death and/or investigate the pathologies leading to death on the instruction of a medicolegal authority.1 Traditionally, this has involved a variable degree of opening the body, direct observation, tissue sampling and special tests (histology, microbiology, toxicology, etc), generally termed an invasive autopsy.2 At the start, it is fully accepted that those practising forensic pathology, where a full autopsy and a wide range of ancillary tests, will generate a very high degree of confidence in the autopsy findings. However, society does not request this level of confirmation with regard to community and hospital deaths—unless there is a medicolegal/criminal issue under consideration. It is also accepted that medically certified causes of death have an appreciable error rate with missed significant diagnoses when compared with a full invasive autopsy.3 Given that it would be impractical to subject every single death in this country to a full invasive/forensic autopsy, a pragmatic balance needs to be sought for society. A clinical impression formed over a period of time, variably supported by antemortem tests, remains sufficient for natural hospital and community/general practitioner cause of death certification. Non-invasive postmortem CT scan radiology autopsy review (PM-CT) in the last 10 years has been increasingly used in the UK, mainly on an episodic relative-request basis, rather than as a tool applied to all mortuary cases.4 Some work on the accuracy of such studies has been performed, and it has been seen that non-invasive and minimally invasive autopsy methods may serve as an adjunct or alternative to conventional autopsies. They are more acceptable to relatives, but are less accurate than the reference standard (ie, a full open/invasive autopsy with fully histology and other tests).5 The use of PM-CT requires a slightly …
An Intensity MTF Theory for Coherent Imaging.

C. J. Reinheimer,C. Wiswall

DOI: https://doi.org/10.1364/AO.8.000947

IF: 1.9

1969-05-01

Applied Optics

Abstract:The effect that any parameter of a holographic or coherent imaging system would have on the resultant image is normally described by an amplitude modulation transfer function. We show here that an intensity modulation transfer function (MTF) can be used to analyze the coherent systems if diffuse targets are employed and if the usable area image.
Frequency of Kell and Rh alloantibodies in Iranian Thalassemia Patients in Khorasan Razavi Province, Iran

Farzad Mollahoseini Foomani,Mohammad Hadi Sadeghian,Saeede Bagheri,Zahra Badiee,Reihane Bazargani,Zahra Aryanpour,Saeid Hallajiayan,Seyyede Fatemeh Shams

DOI: https://doi.org/10.18502/ijhoscr.v17i1.11707

2023-01-01

Abstract:Background: Thalassemia is an inherited disease with anemia and hemolysis. Blood transfusion is a routine treatment for thalassemia patients; alloimmunization is one of the complications of blood transfusion, which is very serious for these patients, especially girls and young women. Materials and Methods: In this cross-sectional study, 446 thalassemia patients were examined. Demographic information of patients was extracted and recorded. The phenotype of ABO, Rh, and Kell antigens (tube method) with antisera from IMMUNDIANOSTICA Company (Germany) and the frequency of alloantibodies were determined. Results: 55.8% of the studied individuals were male, and 44.2% were female. Mean age of the studied patients was 19.94±10.63. The alloantibodies were detected in 7.5% of cell-pack receivers. The most prevalent phenotype of the ABO system was the O blood group (37.4%), and the most abundant antigen of the Rh group was 'e', which was found in 99.8% of the studied population. The most common alloantibody detected was Anti K (38.2%); concerning kell phenotype, (K_k+) and (K+k+) were found in 99.3% and 0.7% of patients, respectively. The frequency of Anti-D, Anti-C, Anti-c, and Anti-E was 23.5%, 14.7%, 2.9%, and 14.7%, respectively. Conclusion: According to the results of this paper, finding the compatible packed cells in terms of Kell and Rh systems antigens in addition to the ABO blood group is recommended to decrease the rate of alloantibodies in thalassemia patients.
Frequency of ABO and Rh Blood Groups Among Blood Donors in the Hail Region of Saudi Arabia

Reem Eltayeb

DOI: https://doi.org/10.7759/cureus.69195

2024-09-11

Cureus

Abstract:Objective: Proper blood bank inventory management and safe, efficient blood transfusion services require a thorough understanding of ABO and Rh(D) blood group distributions in specific populations. The objective of this research was to evaluate the distribution of ABO and Rh blood types among different ethnic blood donors in the Hail region of Saudi Arabia and compare the results to those of other populations. Methodology: Data from 3,166 blood donors were analyzed retrospectively. Blood bank records provided sociodemographic information as well as blood group phenotypes. Descriptive statistics were employed. The distribution of ABO and Rh blood types was statistically examined using the chi-square test. Results: The study identified a total of 3,166 blood donors, with the majority being males (3,083 (97.4%)). The median age of the donors was 35 years, with an interquartile range of 30-41 years. Of the cohort, 1,425 (45%) consisted of young donors, defined as individuals aged 30-41 years. The O blood type accounted for 1,409 (44.5%) of all types, making it the most prevalent. The next most common blood types were B at 837 (26.4%), A at 741 (23.4%), and AB at 179 (5.7%). When combined, O positive was the most prevalent type, accounting for 1,226 (38.7%) of the total. This was followed by type B positive at 745 (23.5%), type A positive at 651 (20.6%), O negative at 183 (5.8%), AB positive at 171 (5.3%), B negative at 92 (2.9%), A negative at 90 (2.8%), and AB negative at eight (0.3%). Conclusion: According to the results, out of all the ABO phenotypes, O was the most common. B, A, and AB came next. In addition, Rh(D) positivity was observed in 88.2% of the donors. These results have considerable consequences for blood transfusion strategies in the Hail region.
Molecular patterns of alpha-thalassemia in the kingdom of Saudi Arabia: identification of prevalent genotypes and regions with high incidence

Hayaa M Alhuthali,Eman F Ataya,Alaa Alsalmi,Triq E Elmissbah,Khalaf F Alsharif,Hind A Alzahrani,Ahad Amer Alsaiari,Mamdouh Allahyani,Amal F Gharib,Husam Qanash,Heba M Elmasry,Doha Elsayed Hassanein

DOI: https://doi.org/10.1186/s12959-023-00560-w

2023-11-10

Abstract:Background: Alpha-thalassemia (α-thalassemia) is one of the most common monogenic diseases in Saudi Arabia and is associated with significant morbidity. Premarital testing programs in Saudi Arabia reduce the burden of hemoglobinopathy disorders, and ongoing monitoring is required. We aimed to explore the molecular nature of α-globin genes and identify the most common genotypes and regions with a high risk of α-thalassemia in Saudi Arabia. Methods: This retrospective study was conducted between January 2021 and December 2022. Six hundred twenty-five samples from patients with microcytic hypochromic anemia in Saudi Arabia were analyzed using reverse dot blot hybridization (RDBH)-based multiplex-PCR, which screens for the known 21 mutations of α-globin genes. Results: Seven mutations in the α-globin gene were identified in 88.96% (556) patients. The most frequent abnormality of a-globin genes was -α3.7 (62.3%), followed by α2IVS1(-5nt) (20.7%) and α2 polyA-1 (α2T.Saudi) (14.1%). Interestingly, α2 polyA-2 (α2T.Turkish) was identified in Saudi and presented with -MED, causing Haemoglobin H disease. The incidence of α-thalassemia in Saudi Arabia's cities showed significant differences (P = 0.004). Jeddah City had the highest percentage of cases (25%), followed by Makkah (23%), Taif (13.3%), and Al-Ahassa (12.4%). Conclusion: The study provides current knowledge about the molecular nature of α- thalassemia, highlights the common genotypes that could contribute to disease occurrence in the Saudi population, and sheds light on Saudi regions with a high incidence. It also recommends further studies in a larger population and with differently composed molecular assays to verify these findings.
Serological markers of transfusion transmissible infections and ABO blood groups in Najran, Saudi Arabia

Ahmad A Alshehri,Ahmad Adebayo Irekeola,Mohammed Merae Alshahrani,Khaja Shameem Mohammed Abdul,Saeed Ahmed Asiri,Banan F Aboluluy,Ahmed Abdullah Al Awadh,Abdulaziz Hassan Alhasaniah,Ibrahim Abdullah Almazni,Saleh A Alshamrani,Abdullah J Alshahrani,Ahmad M Saif,Osman Ae Elnoubi,Abdulrahim R Hakami,Abdulrazzag Abdulaziz Othman,Mansor H Almohi

DOI: https://doi.org/10.15537/smj.2024.45.7.20240338

Abstract:Objectives: To ascertain the prevalence of transfusion transmissible infections (TTIs) across diverse donor groups in the Najran province. Additionally, to establish a potential association between the development of TTI and the donors' blood group, as determined by the ABO/Rh blood grouping system. Methods: Blood donation data of 4120 donors, spanning from January to December 2020, were retrospectively reviewed. The blood were screened for TTI markers, including hepatitis B surface antigen (HBsAg), anti-hepatitis B core (anti-HBc), anti-hepatitis C virus (anti-HCV), anti-human immunodeficiency viruses 1 and 2 (anti-HIV1&2), anti-human T-lymphotropic virus types 1 and 2 (anti-HTLV-1&2), and syphilis antigen. Results: Positive TTI markers were detected in 10.9% of the donors. The most detected TTI marker was anti-HBc (8.9%), followed by HBsAg (0.7%). Other markers were individually detected in <1% of the donors. Anti-HBc-positive was significantly elevated among non-Saudi blood donors. There was an association between age groups and anti-HCV (p=0.002), anti-HTLV (p=0.004) and syphilis antigen (p=0.02) markers positivity. The AB positive blood group exhibited the most positivity for TTI markers, followed by O positive blood group. Similarly, association was found between ABO group and HBsAg (p=0.01), anti-HBc (p=0.001), and anti-HCV (p<0.001) markers positivity. Conclusion: Emphasis on implementing robust screening measures for donated blood is underscored by this study. There is the need for future study to extensively evaluate TTI status to enhance our understanding of the trend in TTI.
The Prevalence of Transfusion-Transmitted Diseases Among Blood Donors in the Central Blood Bank in Makkah, Saudi Arabia

Mohammad Albshri,Palanisamy Manikandan,Mamdouh Allahyani,Abdulelah Aljuaid,Mazen M Almehmadi,Kamal Alzabeedi,Mohamed Babalgaith,Mosa Alghamdi,Faris Alharbi,Mohammed Alhazmi

DOI: https://doi.org/10.7759/cureus.48881

2023-11-16

Cureus

Abstract:Background This study aimed to analyze the health and demographic characteristics of blood donors in Makkah, Saudi Arabia, and assess the prevalence and correlation of two markers related to hepatitis B infection: hepatitis B virus surface antigen (HBsAg) and anti-hepatitis B virus surface antibody (HBsAb). Materials and methods The study used a retrospective design and collected data from the Central Blood Bank in Makkah, Saudi Arabia, in 2022. The sample size was 7,875 blood donors. The study used various methods, such as serological testing, nucleic acid testing (NAT), and statistical analysis. The data were analyzed using Pearson correlation to examine the relationships between different variables. Results The predominant age group was 29-39 years, accounting for 46.9% of the total donors. In terms of blood types, O+ve was the most common, representing 40.3% of the donors. The investigation into infectious markers revealed overall low levels of reactivity among donors. For HBsAg, a marker of active hepatitis B infection, only 0.36% of the units were reactive. Conversely, the anti-HBsAb, which indicates immunity to hepatitis B, was reactive in 6.83% of the units. The correlation analysis illuminated some critical relationships. The total number of units tested had a statistically significant, albeit weak, positive relationship with HBsAg reactivity, shown by a Pearson correlation coefficient of 0.030 and a p-value of 0.008. Conversely, the total number of units tested and anti-HBsAb reactivity showed a moderate negative correlation, with a Pearson correlation coefficient of -0.437 and a p-value of less than 0.001. However, no significant correlation was identified between HBsAg and anti-HBsAb reactivity, indicating that active infection and immunity status might not be directly linked. Conclusion This extensive study provides in-depth insights into the sociodemographic characteristics of blood donors and the prevalence of key infectious markers within this population. It underlines the imperative of rigorous screening of blood units, particularly given the low immunity levels to hepatitis B identified. Also, the study showed the importance of screening blood units and vaccinating people against hepatitis B. It also suggested the need for more research on blood safety and infection-immunity relationships.
Alkaline Phosphatase Is Associated with Red Cell Alloimmunization in the Pulmonary Hypertension and Hypoxic Response (PUSH) Sickle Cell Disease Cohort

Victoria Brooks,Oluwalonimi Adebowale,Victor R. Gordeuk,Sergei Nekhai,James G. Taylor

DOI: https://doi.org/10.1182/blood-2020-143036

IF: 20.3

2020-11-05

Blood

Abstract:Background: Blood transfusion is a common therapy for sickle cell disease (SCD). Although, highly effective, a major limitation is development of alloantibodies to minor blood group antigens on donor red cells. Alloimmunization has a prevalence of 2-5% for transfusions in the general population, but it is significantly higher in SCD. Risk factors for alloimmunization have been poorly characterized, although number of lifetime transfusions is an important risk factor. Alloimmunization has been clinically observed in children with a prevalence of about 7%. With development of each antibody, blood donor matching becomes increasingly difficult and expensive with an increased risk for transfusion reactions and diminished availability of compatible red cell units for treatment of SCD. The ability to identify risk factors for developing alloantibodies would be beneficial for clinicians. To identify markers for alloimmunization in SCD, we have analyzed children and adults who developed this complication. Methods: We analyzed The Pulmonary Hypertension and Hypoxic Response in Sickle Cell Disease (PUSH) study, which enrolled n=468 pediatric and n=59 adult SCD subjects. In both children and adults, alloimmunization cases were defined as a history of at least 1 alloantibody. Controls in both cohorts were defined as subjects with no history of alloantibodies and receipt of more than 10 lifetime red cell transfusions. All others within the study who did not meet these criteria were assigned to a third comparison group. To identify differences between cases, controls and all others, we performed univariate analyses (using ANOVA or Kruskal Wallace where appropriate) for clinical parameters and laboratories. Case control comparisons were also performed for selected variables and plasma levels for 11 cytokines. Results were further analyzed using regression modeling. Results: The overall prevalence of alloimmunization was 7.3% among children (34/468 subjects; median age 12, range 3-20 years) compared to 28.8% in adults (17/59 subjects; median age 37, range 18-73 years). When only considering those with >10 lifetime transfusions, the prevalence was considerably higher at 29.3% and 54.8% in children and adults, respectively. At the same time, 8 pediatric (23.5%) and 5 adult (29.4%) alloimmunization cases had received fewer than 10 transfusions. In a 3-way pediatric cohort comparison (cases, controls and all others), risk factors associated with alloimmunization included SS genotype, older age and markers of more severe disease (higher ferritin, WBCs, platelets and total bilirubin). Comparison of cases to controls showed alkaline phosphatase (P=0.05) was significantly lower in cases, whereas AST (P=0.02) was significantly higher even with adjustment for age. Levels of plasma cytokines MCP-1 (P=0.01) and IFNgamma (P=0.08) were lower in cases from a subset of the pediatric cohort. In adults, only 4/59 (6.8%) subjects had never received a lifetime transfusion (all non-SS). In the adult 3-way comparisons, only SS genotype and higher ferritin were associated with alloimmunization. The adult case control analysis showed higher absolute monocyte count (P=0.02), absolute eosinophil count (P=0.04) and absolute basophil count (P=0.008) in association with alloimmunization cases. In addition, alkaline phosphatase was again significantly lower among cases (P=0.02) as seen in the pediatric cohort. There were no significant differences in cytokine levels among adults. Conclusions: When considering only transfused SCD patients, the prevalence of alloimmunization is higher than 30%. As seen in prior studies, higher lifetime red cell transfusions are an important risk factor especially among adults where most patients have received transfusions. Children who develop alloantibodies appear to have laboratory markers of more severe disease, but this is not observed in adults. A novel association observed across both pediatric and adult subjects is a significantly lower serum alkaline phosphatase in those with alloantibodies. The results of this study suggest a need for improved tracking of red cell transfusion therapy in the US for SCD patients due to a high prevalence of alloimmunization. Further study is also needed to elucidate the significance of the alkaline phosphatase association. Disclosures Gordeuk: CSL Behring: Consultancy, Research Funding; Global Blood Therapeutics: Consultancy, Research Funding; Novartis: Consultancy; Ironwood: Research Funding; Imara: Research Funding.

hematology
Contextualizing prophylactic red blood cell antigen matching in the lifelong care of sickle cell disease and thalassaemia patients

Eric A. Gehrie,Garrett S. Booth

DOI: https://doi.org/10.1111/bjh.19878

2024-12-03

British Journal of Haematology

Abstract:Alloimmunization to minor red blood cell antigens has been linked to patient morbidity and mortality, especially among people living with sickle cell disease and transfusion‐dependent thalassaemia. Prophylactic antigen matching is commonly used to prevent alloimmunization, but the evidence supporting this common practice is very limited. The report by Wolf et al. summarizes the latest literature on this topic and importantly finds that there is insufficient evidence to recommend prophylactic extended antigen matching (beyond ABO, RhD, RhCcEe and K). In an era of chronic blood shortages, this approach may help to assure patient access to elective surgery and cellular therapies, while preserving the supply of extensively antigen‐matched red cells for patients with specific needs. Commentary on: Wolf et al. Red cell specifications for blood group matching in patients with haemoglobinopathies: An updated systematic review and clinical practice guideline from the International Collaboration for Transfusion Medicine Guidelines. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19837

hematology

Ultrasonic aspiration in coronary artery surgery.

Prevalence of Red Blood Cell Alloimmunization Among Pediatric Patients With Sickle Cell Disease in Saudi Arabia

Red blood cell alloimmunization in blood transfusion-dependent β thalassemia major patients in Sana'a City-Yemen

In vivo X-ray fluorescence estimation of bone lead concentrations in Queensland adults.

Red blood cell extended antigen typing in Omani patients with sickle cell disease to enhance daily transfusion practice

Statistical Computing Environments and the Practice of Statistics in the Biopharmaceutical Industry

Red blood cell alloimmunization in transfused patients with myelodysplastic syndromes: a retrospective study from northern China

Red cell alloantibodies in beta-thalassaemia major patients' blood referring to the regional blood transfusion center of Tehran, Iran

RH genotypes and red cell alloimmunization rates in chronically transfused patients with sickle cell disease: A multisite study in the USA

Red Cell Alloimmunization in Repeatedly Transfused Sudanese Patients with leukemia in Northern Sudan

Red blood cell alloimmunizations in thalassaemia patients with regular transfusion in China: A systematic review and meta-analysis

Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia

The effects of postmortem CT scanning all cases entering a UK public mortuary: a 3-month pilot

An Intensity MTF Theory for Coherent Imaging.

Frequency of Kell and Rh alloantibodies in Iranian Thalassemia Patients in Khorasan Razavi Province, Iran

Frequency of ABO and Rh Blood Groups Among Blood Donors in the Hail Region of Saudi Arabia

Molecular patterns of alpha-thalassemia in the kingdom of Saudi Arabia: identification of prevalent genotypes and regions with high incidence

Serological markers of transfusion transmissible infections and ABO blood groups in Najran, Saudi Arabia

The Prevalence of Transfusion-Transmitted Diseases Among Blood Donors in the Central Blood Bank in Makkah, Saudi Arabia

Alkaline Phosphatase Is Associated with Red Cell Alloimmunization in the Pulmonary Hypertension and Hypoxic Response (PUSH) Sickle Cell Disease Cohort

Contextualizing prophylactic red blood cell antigen matching in the lifelong care of sickle cell disease and thalassaemia patients